Welcome

Beactica is a specialist drug discovery company utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel therapeutics. As well as progressing its own drug discovery programmes, Beactica offers partnerships for fragment-based lead generation using its proprietary discovery platform and services in the area of SPR biosensor-based interaction analysis.

Founded in 2006 based on research carried out at Uppsala University, Beactica has established a reputation as the leader in SPR biosensor-based small molecule drug discovery.

Latest News

Publications

Upcoming events

9–12 January 2017, Beactica holds meetings in conjunction with the 35th Annual JP Morgan Healthcare Conference in San Francisco, USA.
7–9 November 2016, Beactica participates in BIO-Europe 2016 in Cologne, Germany.